tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Xenon Pharmaceuticals price target lowered to $47 from $50 at Wells Fargo

Wells Fargo analyst Mohit Bansal lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $47 from $50 and keeps an Overweight rating on the shares. After enrollment completion was pushed back from the second half of 2024 and now top-line data pushed to early 2026, the firm can see investor concerns around X-TOLE2 program and lack of catalyst this year. Though not statistical significant, Mt. Sinai data was reassuring for MDD activity, Wells adds.

Elevate Your Investing Strategy:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1